Syros Announces Clinical Updates and 2023 Strategic Priorities

Author's Avatar
Jan 09, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.